Fig. 4

CAR-T distribution in NHL patients. a. Flow diagram of the experiment. After CAR-T cell infusion, 13 patients were followed by monitoring disease response, peripheral CAR-T cell number, adverse events including CRS and ICANS, routine blood analysis, and blood biochemistry. b. DOR of 13 patients. The first response was evaluated on day 28 and the longest monitoring duration was 15 months(DOR: Duration of Response). c. PET-CT data of Patient F0121 and F0122 at baseline and day 28 after CAR-T infusion. The tumors indicated by red arrows (Parameter: WW200 WL60 Fusion-70% SUVrange-0 to 6). d. The level of CD19⁺ cells in the peripheral blood of each patient after CAR-T cell therapy. e. Changes of CAR-T cells in peripheral blood after infusion in 13 patients. Red blood cells were removed followed by washing and re-suspension. The separated cells were stained with PE-conjugated anti-CD3 and FITC-conjugated anti-CAR. Data were acquired from the stained cells using BD FACS Callibur cytometry. The results were evaluated with FlowJo software. f. Average CAR-T cell peak in 13 patients. The average peak concentration of CAR-T cells was about 10⁸/L detected by FACS. g. The peak number of CAR-T cells in the peripheral blood of patients in CR, PR and PD groups